TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01789736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG286 Ophthalmic Solution 0.5%
Description: PG286 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 Ophthalmic Solution 0.5%
Description: AR-12286 Ophthalmic Solution 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost Ophthalmic Solution 0.004%
Description: Travoprost Ophthalmic Solution 0.004%
Study: NCT03942809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effectiveness
Description: Effectiveness and Practicability in anesthetized patient under controlled conditions
Study: NCT04429997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of fibrosynovial tissue
Description: Remove of fibrosynovial tissue at the superior border of patella

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-removal of fibrosynovial tissue
Description: Do not remove of fibrosynovial tissue at the superior border of patella
Study: NCT02394951

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: Anticonvulsant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Anticonvulsant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical, matching inactive substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical, matching inactive substance
Study: NCT03201705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst + Tonic
Description: Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
Study: NCT02739295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant granulocyte - colony stimulating factor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Study: NCT01911065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax™
Description: In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
Study: NCT02343055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management and Self-Management Education
Description: A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Case Management and Self-Management Education
Description: A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
Study: NCT02154789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polidocanol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infra-red coagulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Study: NCT02571049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-11
Description: Sumatriptan 3 mg versus 6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-11
Description: Sumatriptan 3 mg versus 6 mg
Study: NCT02182557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL 801 CL Dry Syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen Fumarate Dry Syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WAL 801 CL Dry Syrup placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen Fumarate Dry Syrup placebo
Study: NCT03253874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Pre-Op Testing for Cataract Surgeries
Description: Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
Study: NCT00546130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin
Description: Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
Study: NCT03846141

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation of room air for 20 min per day during 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Inhalation of 4% hydrogen for 20 min per day during 7 days
Study: NCT02472197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Description: The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hysteroscopic resection
Description: The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
Study: NCT04419883

Intervention type: DEVICE
Intervention: McMurray Enhanced Airway
Description: Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
Study: NCT02036879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin (norethindrone acetate and ethinyl estradiol)
Description: This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
Study: NCT02825784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renastart
Description: Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
Study: NCT01439152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343
Description: BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343 (Expansion)
Description: BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343 (1.8 mg/kg)
Description: BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Study: NCT02858622

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Study: NCT01524575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and oxaliplatin
Description: Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
Study: NCT04008472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedecine
Description: Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
Study: NCT01781546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drug-eluting balloon (DEB)
Description: The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is \>20mm or stent malapposition is suspected).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent (BMS)
Description: The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length \>20mm or stent malapposition is suspected).
Study: NCT02233777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin capsules 150 mg of Dexa Medica
Description: Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland
Description: Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study: NCT04403334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Ophthalmic
Description: 0.1 ml of unpreserved 0.5% levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Ophthalmic
Description: 0.1 ml of unpreserved 0.5% moxifloxacin
Study: NCT01488890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever
Description: 0.5 mL, Subcutaneous
Study: NCT04407754

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inositol supplement
Description: Inositol supplements given to inositol arm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo supplement given to placebo arm
Study: NCT02780648

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Study: NCT01439152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343 (2.2 mg/kg)
Description: BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Study: NCT03542773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: 18F-DCFPyL with whole body PET/CT scan
Study: NCT01546350

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGD
Description: array CGH after blastocyst biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PGD
Description: PGD using blastocyst biopsy and testing of the biopsy by array CGH
Study: NCT01558011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin, Docetaxel
Description: Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy.
Study: NCT02868866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
Study: NCT02763787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo
Study: NCT01496482

Intervention type: OTHER
Intervention: Only measurements done on subjects in both groups.
Description: As study compared specific diagnostic procedures, no intervention was done or compared.

Intervention type: OTHER
Intervention: Only measurements done on subjects in both groups.
Description: As study compared specific diagnostic procedures, no intervention was done or compared.
Study: NCT02667587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab Placebo
Study: NCT03343301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Administered by intravenous infusion over approximately 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Administered by intravenous infusion over approximately 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours.
Study: NCT03430206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
Study: NCT00551941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMP-7 in adjunct to fresh frozen allograft
Description: non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allograft together with DBM
Description: non-union of diaphysary tibial fractures treated with allograft together with DBM
Study: NCT03536299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task gait
Description: During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. In addition to performing the gait training activities, you will be asked to perform thinking tasks at the same time. These pre-recorded questions or prompts will be provided to you through headphones and a portable music player. This is to help ensure that the PT is able to focus on giving you feedback about your walking ability and answers to the thinking tasks, and on your safety. At the end of each session, you will have walked for a total walking time of 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-task gait
Description: During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. At the end of each session, you will have walked for a total walking time of 20 minutes.
Study: NCT04266067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF exercise
Description: Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frenkel exercise
Description: The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
Study: NCT02530515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex Vivo-activated Autologous Lymph Node Lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01516905

Intervention type: DRUG
Intervention: NM404
Description: injection of either 2.0mCi or 5.0mCi I-124 NM404
Study: NCT04730102

Intervention type: PROCEDURE
Intervention: Rectal washout
Description: Rectal washout is performed intraoperatively before transection and means irrigation of the rectum following the closure of the rectal lumen below the tumour with a purse string suture. Rectal washout is performed with a total of 500 ml sterile water. Fluid samples are collected after every 100 ml by instilling 50 ml of saline after each washout. A sixth sample is collected from the presacral cavity.
Study: NCT01625299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten and dry milk
Description: 0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour 1.0 g/kg/day
Study: NCT04386811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
Study: NCT03726710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Pressure measurement and pharmacy
Description: Blood Pressure monitoring by barber, Blood pressure measurement and management by pharmacist in person and through telemedicine
Study: NCT04497454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EIT-Group
Description: A mechanical ventilation strategy with the main goal to maintain DP \< 16 cmH2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ARDSNet
Description: Low PEEP-FiO2 table ARDS Network ventilation protocol